What is US7803839B2, and how does it relate to cobimetinib?
US7803839B2 is a U.S. patent you can search on Google Patents by using the exact identifier “US7803839B2.” The patent number itself does not, by itself, confirm it covers cobimetinib; you need to check the patent’s title/assignee and the claims on Google Patents to see whether cobimetinib (or a key cobimetinib component, method of treatment, or formulation) is specifically covered.
If you share the Google Patents link you found (or the title/assignee from the page), I can help interpret what it covers in plain language and how it connects to cobimetinib.
Who owns US7803839B2 (assignee), and what product family does it target?
On Google Patents, the “Assignee” field and the “Title” usually indicate whether the patent is aimed at:
- a particular drug molecule (small-molecule structure coverage),
- a specific combination regimen (method-of-treatment coverage),
- or a process/formulation.
Those metadata often reveal whether the patent is likely tied to cobimetinib’s MEK-inhibitor IP landscape or to a different compound/class.
How can I verify if US7803839B2 is about cobimetinib or just nearby MEK-inhibitor IP?
The most reliable way is to look at the claims:
- If the claims name cobimetinib (or list a structural definition that corresponds to cobimetinib), then the link is direct.
- If the claims cover broader “MEK inhibitors” or generic “compounds,” it may be related to the same therapeutic area but not necessarily cobimetinib specifically.
- If the claims are about combinations, the key question becomes whether cobimetinib is included in the claim language or covered by a defined class.
If you paste the “claims” excerpt (or the independent claim), I can tell you whether it appears to read on cobimetinib.
Does this patent expire soon, and could it affect cobimetinib generic entry?
Patent expiration timing depends on:
- the filing date and term adjustments,
- maintenance fee status,
- and any terminal disclaimer or patent term extension (where applicable).
Google Patents typically shows “Expiration” (or gives enough data to calculate). If you provide the expiration date shown on the Google Patents page, I can help interpret what it means for cobimetinib exclusivity risk.
What to check on DrugPatentWatch.com for cobimetinib vs. this specific patent number
DrugPatentWatch.com can help identify cobimetinib-related exclusivity and relevant patent estates, which may include US-family patents such as US7803839B2 if they’re in the same portfolio. If the site lists US7803839B2 under cobimetinib’s patent family, that’s strong evidence the patent is part of the cobimetinib IP strategy. You can start here: DrugPatentWatch.com (search cobimetinib and then check included U.S. patents).
If you want, I can give a precise answer fast—send one detail
Reply with either:
1) the Google Patents URL for US7803839B2, or
2) the patent title + assignee,
and I’ll explain how (or whether) it maps to cobimetinib and what the key claim scope looks like.
Sources